FDA Letters To AstraZeneca And Novo Nordisk Approve Addition Of Information About Increased Risk For Medullary Thyroid Carcinoma (MTC)

 
SUMMARY: Each of these March 2015 FDA letters, to AstraZeneca and to Novo Nordisk respectively, contain this paragraph:

We also refer to our letter dated October 7, 2014, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for long-acting GLP-1 receptor agonist products. This information pertains to the risk of medullary thyroid carcinoma.

In both AstraZeneca’s Bydureon Prescribing Information and Novo Nordisk’s Victoza Prescribing Information, the March 2015 label revisions concerning medullary thyroid carcinoma (MTC) can be seen in the so-called “Black Box” warning at the beginning of that document as well as at part 5.1 Risk of Thyroid C-cell Tumors in the Warnings and Precautions section.

As you may know, these diabetes drugs, Bydureon and Victoza, are alleged to have caused thyroid cancer and pancreatic cancer in drug injury lawsuits filed against the responsible pharmaceutical companies.

[Read this article in full at original source]

_____________________________________________________________________________

Bydureon / Byetta / Januvia / Victoza
Free Case Evaluation

Strictly Confidential, No Obligation

______________________________________________________________________________